New hope for brain cancer: targeted drug combo aims to keep lymphoma in check
NCT ID NCT07405255
First seen Feb 13, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study tests a drug called zanubrutinib combined with chemotherapy for people newly diagnosed with central nervous system lymphoma. After initial treatment, those who respond well continue zanubrutinib for 2 years to prevent the cancer from coming back. The trial includes 19 participants and focuses on how many achieve complete remission after 6 cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
Shanghai, Shanghai Municipality, 200025, China
Conditions
Explore the condition pages connected to this study.